


PTO/SB/08A (6-95)



PTO/SB/08A (6-95)

Approved for use through 09/30/98, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box

1449A/PTO		U.S. Department of Commerce Patent and Trademark Office		Complete if Known	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (use as many sheets as necessary)				Application Number	09/125,887
				Filing Date	12 March 1997 (Inter.)
				First Named Inventor	Boon-Falleur et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	EX96002 -US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, country, where published, source.	T
DMK	PA	Chen et al., Therapeutic Antitumor Response After Immunization with a Recombinant Adenovirus Encoding a Model Tumor-Associated Antigen, The Journal of Immunology 156 (1), 224-231 (1996)	
I	PB	van der Bruggen et al., A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma, Science 254, 1643-1647 (1991)	
✓	PC	Warnier et al., Induction Of A Cytolytic T-Cell Response In Mice With A Recombinant Adenovirus Coding For Tumor Antigen P815A,	

EXAMINER SIGNATURE <u>DMK</u>	DATE CONSIDERED <u>11/18/99</u>
-------------------------------	---------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for